John G Ullman & Associates Inc Bristol Myers Squibb CO Transaction History

John G Ullman & Associates Inc

  • $649 Million
  • Q3 2024

A detailed history of John G Ullman & Associates Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, John G Ullman & Associates Inc holds 158,350 shares of BMY stock, worth $9.15 Million. This represents 1.26% of its overall portfolio holdings.

Number of Shares
158,350
Previous 227,815 30.49%
Holding current value
$9.15 Million
Previous $9.46 Million 13.39%
% of portfolio
1.26%
Previous 1.5%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
SELL
$39.66 - $51.75 $2.75 Million - $3.59 Million
-69,465 Reduced 30.49%
158,350 $8.19 Million
Q2 2024

Aug 08, 2024
SELL
$40.25 - $52.99 $4.24 Million - $5.59 Million
-105,417 Reduced 31.63%
227,815 $9.46 Million
Q1 2024

May 06, 2024
SELL
$47.98 - $54.4 $1.32 Million - $1.5 Million
-27,549 Reduced 7.64%
333,232 $18.1 Million
Q4 2023

Jan 31, 2024
BUY
$48.48 - $57.85 $274,008 - $326,968
5,652 Added 1.59%
360,781 $18.5 Million
Q3 2023

Nov 01, 2023
SELL
$57.89 - $64.73 $263,399 - $294,521
-4,550 Reduced 1.27%
355,129 $20.6 Million
Q2 2023

Aug 21, 2023
SELL
$63.71 - $70.74 $498,084 - $553,045
-7,818 Reduced 2.13%
359,679 $23 Million
Q1 2023

May 05, 2023
SELL
$65.71 - $74.53 $599,800 - $680,309
-9,128 Reduced 2.42%
367,497 $25.5 Million
Q4 2022

Feb 08, 2023
SELL
$68.48 - $81.09 $247,212 - $292,734
-3,610 Reduced 0.95%
376,625 $27.1 Million
Q3 2022

Oct 19, 2022
SELL
$0.13 - $76.84 $508 - $300,521
-3,911 Reduced 1.02%
380,235 $27 Million
Q2 2022

Jul 27, 2022
SELL
$72.62 - $79.98 $96,221 - $105,973
-1,325 Reduced 0.34%
384,146 $29.6 Million
Q1 2022

Apr 29, 2022
SELL
$61.48 - $73.72 $250,408 - $300,261
-4,073 Reduced 1.05%
385,471 $28.2 Million
Q4 2021

Jan 26, 2022
SELL
$53.63 - $62.52 $26,975 - $31,447
-503 Reduced 0.13%
389,544 $24.3 Million
Q3 2021

Nov 02, 2021
SELL
$59.17 - $69.31 $46,330 - $54,269
-783 Reduced 0.2%
390,047 $23.1 Million
Q2 2021

Jul 23, 2021
SELL
$61.91 - $67.42 $327,565 - $356,719
-5,291 Reduced 1.34%
390,830 $26.1 Million
Q1 2021

Apr 22, 2021
SELL
$59.34 - $66.74 $367,908 - $413,787
-6,200 Reduced 1.54%
396,121 $25 Million
Q4 2020

Feb 05, 2021
SELL
$57.74 - $65.43 $307,638 - $348,611
-5,328 Reduced 1.31%
402,321 $25 Million
Q3 2020

Nov 06, 2020
SELL
$57.43 - $63.64 $122,957 - $136,253
-2,141 Reduced 0.52%
407,649 $24.6 Million
Q2 2020

Jul 29, 2020
SELL
$54.82 - $64.09 $37,990 - $44,414
-693 Reduced 0.17%
409,790 $24.1 Million
Q1 2020

Apr 14, 2020
SELL
$46.4 - $67.43 $197,896 - $287,588
-4,265 Reduced 1.03%
410,483 $22.9 Million
Q4 2019

Jan 29, 2020
SELL
$49.21 - $64.19 $23,620 - $30,811
-480 Reduced 0.12%
414,748 $26.6 Million
Q3 2019

Oct 21, 2019
BUY
$42.77 - $50.71 $2.44 Million - $2.89 Million
56,960 Added 15.9%
415,228 $21.1 Million
Q2 2019

Aug 02, 2019
BUY
$44.62 - $49.34 $4.03 Million - $4.46 Million
90,311 Added 33.7%
358,268 $16.2 Million
Q1 2019

Apr 30, 2019
BUY
$45.12 - $53.8 $1.41 Million - $1.68 Million
31,158 Added 13.16%
267,957 $12.8 Million
Q4 2018

Jan 29, 2019
BUY
$48.76 - $63.23 $3.4 Million - $4.4 Million
69,659 Added 41.68%
236,799 $12.3 Million
Q3 2018

Nov 02, 2018
SELL
$55.19 - $62.25 $101,273 - $114,228
-1,835 Reduced 1.09%
167,140 $10.4 Million
Q2 2018

Jul 23, 2018
BUY
$50.53 - $62.98 $1.83 Million - $2.28 Million
36,124 Added 27.19%
168,975 $9.35 Million
Q1 2018

Apr 19, 2018
SELL
$59.92 - $68.98 $82,390 - $94,847
-1,375 Reduced 1.02%
132,851 $8.4 Million
Q4 2017

Jan 31, 2018
BUY
$59.94 - $65.35 $49,150 - $53,586
820 Added 0.61%
134,226 $8.23 Million
Q3 2017

Nov 03, 2017
BUY
$55.23 - $63.74 $7.37 Million - $8.5 Million
133,406
133,406 $8.5 Million

Others Institutions Holding BMY

# of Institutions
2,536
Shares Held
1.47B
Call Options Held
31.6M
Put Options Held
35M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track John G Ullman & Associates Inc Portfolio

Follow John G Ullman & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email